Correlation between the expression of integrins in prostate cancer and clinical outcome in 1284 patients

Annals of Diagnostic Pathology

Volumn 18, Issue 6, 2014, Pages 343-350

  Heß, Katharina ^a   Böger, Christine ^a   Behrens, Hans Michael ^a   Röcken, Christoph ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Biomarker; Gleason score; Immunohistochemistry; Integrins; Prostate cancer

Indexed keywords

ALPHAV PAN INTEGRIN; ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; ALPHAVBETA8 INTEGRIN; BETA3 INTEGRIN; FORMALDEHYDE; INTEGRIN; MONOCLONAL ANTIBODY; PARAFFIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ANATOMICAL VARIATION; ANTIBODY LABELING; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; CANCER TISSUE; CELL DIFFERENTIATION; CELLS BY BODY ANATOMY; CELLULAR DISTRIBUTION; CORRELATIONAL STUDY; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; OUTCOME ASSESSMENT; PERIPHERAL NERVE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY; TISSUE SECTION; ANIMAL; GERMANY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RABBIT; RETROSPECTIVE STUDY; SURVIVAL;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; GERMANY; HUMANS; INTEGRINS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RABBITS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84923622101     PISSN: 10929134     EISSN: 15328198     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2014.09.001     Document Type: Article

References (34)

1. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res 2009;53: 171-84.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61: 69-90.
3. Sutcliffe PA, Hummel S, Simpson ET, et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: A systematic review. Health Technol Assess 2009;13: 1-260.
4. Wang Y, Balan V, Kho D, Hogan V, et al. Galectin-3 regulates p21 stability in human prostate cancer cells. Oncogene 2013;32: 5058-65.
5. Balan V, Wang Y, Nangia-Makker P, et al. Galectin-3: A possible complementary marker to the PSA blood test. Oncotarget 2013;4: 542-9.
6. Sita-Lumsden A, Dart DA, Waxman J, et al. Circulating microRNAs as potential new biomarkers for prostate cancer. Br J Cancer 2013;108: 1925-30.
7. Pontes J, Reis ST, de Oliveira LCN, et al. Association between integrin expression and prognosis in localized prostate cancer. Prostate 2010;70: 1189-95.
8. Lim ST, Chen XL, Lim Y, et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell 2008;29: 9-22.
9. Xiong J, Balcioglu HE, Danen EH. Integrin signaling in control of tumor growth and progression. Int J Biochem Cell Biol 2013;45: 1012-5.
10. Fornaro M, Manes T, Languino LR. Integrins and prostate cancer metastases. Cancer Metastasis Rev 2001;20: 321-31.
11. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: Lessons and opportunities. Nat Rev Drug Discov 2010;9: 804-20.
12. Malyankar UM, Scatena M, Suchland KL, et al. Osteoprotegerin is an alpha vbeta 3- induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000;275: 20959-62.
13. Erdreich-Epstein A, Shimada H, Groshen S, et al. Integrins alpha(v)beta3 and alpha(v) beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 2000;60: 712-21.
14. Ross FP, Chappel J, Alvarez JI, et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem 1993;268: 9901-7.
15. Yang SB, Du Y, Wu BY, et al. Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer. Cancer Immunol Immunother 2012;61: 335-42.
16. Breuss JM, Gallo J, DeLisser HM, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 1995;108: 2241-51.
17. Liu J, Zeng L, Kennedy RM, et al. betaPix plays a dual role in cerebral vascular stability and angiogenesis, and interactswith integrin alphavbeta8. Dev Biol 2012;363: 95-105.
18. Goel HL, Li J, Kogan S, et al. Integrins in prostate cancer progression. Endocr Relat Cancer 2008;15: 657-64.
19. Goel HL, Alam N, Johnson IN, et al. Integrin signaling aberrations in prostate cancer. Am J Transl Res 2009;1: 211-20.
20. Wittekind C, Meyer HJ. TNM classification of malignant tumors. 7th edition of the Union Internationale Contre Cancer (UICC). 7th ed.Weinheim: Wiley-Blackwell; 2010.
21. Epstein JI, Allsbrook JrWC, AminMB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostate Carcinoma. Am J Surg Pathol 2005;29: 1228-42.
22. Warneke VS, BehrensHM, Boger C, et al. Her2/neu testing in gastric cancer: Evaluating the risk of sampling errors. Ann Oncol 2013;24: 725-33.
23. Boger C, Kalthoff H, Goodman SL, et al. Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression. Virchows Arch 2014;464: 69-78.
24. Goodman S, Grote HJ, Wilm C. Matched rabbit monoclonal antibodies against avseries integrins reveal a novel avb3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open 2012. http://dx.doi.org/10. 1242/bio.2012364.
25. Boger C, Kalthoff H, Goodman SL, et al. Validation and comparison of anti-alpha v beta 3 and anti-alpha v beta 5 rabbit monoclonal versus murine monoclonal antibodies in four different tumor entities. Appl Immunohistochem Mol Morphol 2013;21: 553-60.
26. McCarty Jr KS, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109: 716-21.
27. AlamN, GoelHL, ZarifMJ, et al. The integrin-growth factor receptor duet. J Cell Physiol 2007;213: 649-53.
28. Cooper CR, Chay CH, Pienta KJ. The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 2002;4: 191-4.
29. Pidgeon GP, Tang K, Cai YL, et al. Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta (5) integrin expression. Cancer Res 2003;63: 4258-67.
30. Zheng DQ, Woodard AS, Fornaro M, et al. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 1999;59: 1655-64.
31. Alva A, Slovin S, Daignault S, et al. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI- 6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs 2012;30: 749-57.
32. Bisanz K, Yu J, Edlund M, et al. Targeting ECM-integrin interaction with liposomeencapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005;12: 634-43.
33. Ramsay AG, Marshall JF, Hart IR. Integrin trafficking and its role in cancermetastasis. Cancer Metastasis Rev 2007;26: 567-78.
34. Abdollah F, Boorjian S, Cozzarini C, et al. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patientswith prostate cancer: The impact of competing causes of mortality and patient stratification. Eur Urol 2013;64: 557-64.